SARS-CoV-2 genomic surveillance update
June 2021

Date of report 1 July 2021

Frequency of Variants of Concern (VOC) in South Africa

The Network for Genomics Surveillance (NGS-SA – list of all contributors listed in acknowledgments)\(^1\) has been performing genomic surveillance for SARS-CoV-2 since mid-2020. As of the 1\(^{\text{st}}\) July, 10,396 SARS-CoV-2 genomes from South Africa have been generated and deposited into the GISAID database\(^2\) (Fig 1). Given the progression of the third wave and a preliminary report of the dominance of the Delta variant in KwaZulu-Natal, we report updated data on the frequency of the Delta variant and other VOCs in Gauteng and South Africa, including Alpha and Beta, and Eta (a Variant of Interest [VOI]) which have begun to dominate in other parts of the world due to increased transmissibility and/or immune evasion.

![Graph](image.png)

**Figure 1.** Number of SARS-CoV-2 genomes sequenced in each epidemiological week in 2020 and 2021, in South Africa (10,396 loaded on GISAID, downloaded 1\(^{\text{st}}\) July 2021). All genomes apart from 32 were sequenced by the Network for Genomics Surveillance in South Africa (NGS-SA).

Genomic data for samples collected in May 2021 are available for all 9 provinces, and 70% of 739 genomes from May were the Beta variant (Fig 2). The Alpha, Delta and Eta variants account for 6%, 14% and 1% of the May genomes. For June 2021, genomic data are available for 5 provinces, with 603 sequences
available on GiSAID. Genomes sequenced (n=603) from samples collected in June 2021 shows 36% Beta and 49% Delta variant frequency with the Alpha variant accounting for 6% (Fig 2).

**Figure 2.** Percentage of SARS-CoV-2 clades sequenced in May and June 2021 in South Africa. Variants of Concern (VOC) and Interest (VOI), namely Alpha, Beta, Delta, Kappa and Eta are shaded in different colours, while other clades are shaded in grey. Note that 21A (Delta) includes the AY.2 lineage (n=2, one in May, one in June).

**Frequency of Variants of Concern (VOC) in Gauteng**

Gauteng is currently the epicenter of the third wave in South Africa, accounting for 65% of daily new cases on the 27th June. Of the 266 Gauteng genomes sequenced from May 2021 (epidemiological weeks 17-22), 66% of Gauteng genomes belonged to the Beta variant, while 12%, 15% and 0.8% were Alpha, Delta and Eta variants observed (Fig 3). However, in June 2021 (epidemiological weeks 22-24), 372 Gauteng genomes were sequenced, and the frequency of the Delta variant has increased to 46% (Fig 3), and is increasing by week to 79% (56/71) in week 24. In June, 37% of genomes in Gauteng were Beta variant, 4% were Alpha variant and less than 1% of sequences belonged to the Kappa variant (Fig 3).
Figure 3. Percentage of SARS-CoV-2 clades sequenced in May (epi week 18-21) and June (epi week 22-24) 2021 in Gauteng Province. Variants of Concern (VOC) and Interest (VOI), namely Alpha, Beta, Delta, Kappa and Eta are shaded in different colours, while other clades are shaded in grey. Note that clade 21A (Delta) includes the AY.2 lineage (n=2) in this analysis.

Summary and implications
Sequencing data from specimens collected 2 weeks ago in Gauteng shows a mixture of variants, with the Delta variant increasingly replacing all others, including the Beta variant, in each subsequent week in the month of June. The Delta variant is more transmissible than Beta variant, providing a plausible explanation for this, but also emphasising the need for all individuals in South Africa to limit their movements to essential activities only. Vaccines still show high levels of protection from severe disease caused by the Delta variant.

Acknowledgements
These data are presented on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA), with particular thanks to:

- our colleagues at both private and public testing laboratories, who submit samples for sequencing despite numerous challenges.
- the sequencing teams at the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) at the University of KwaZulu-Natal (UKZN); the Division of Medical Virology at NHLS Tygerberg Hospital, Stellenbosch University (SU); the Division of Medical Virology at NHLS Groote Schuur Hospital, University of Cape Town (UCT); the Division of Virology at NHLS Universitas Academic Laboratories, University of the Free State (UFS); the Division of Virology at NHLS Inkosi Albert Luthuli Central Hospital (IALCH), University of KwaZulu-Natal (UKZN); the Zoonotic Arbo and Respiratory Virus Research Programme (ZARV) and NHLS-Tshwane Academic division (NHLS-
At the NICD, we would like to acknowledge the Centre for Respiratory Diseases and Meningitis, Sequencing Core Facility and Centre for HIV and STIs. In addition, we thank Hyarax Biosciences, Bridge-the-Gap and the Cape Town Immunology Laboratory for rapid and efficient assistance.

Sequencing activities at the NICD were supported by: a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response, a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (grant number 5 U01IP001048-05-00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); the South African Medical Research Council (Reference number SHIPNCD 76756); the Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. [The Fleming Fund is a £265 million UK aid programme supporting up to 24 low- and middle-income countries (LMICs) generate, share and use data on antimicrobial resistance (AMR) and works in partnership with Mott MacDonald, the Management Agent for the Country and Regional Grants and Fellowship Programme.]

References and useful links

1. Global Initiative on Sharing All Influenza Data (GISAID, [https://www.gisaid.org/](https://www.gisaid.org/))


